Try our Advanced Search for more refined results

May 12, 2017

Impax Laboratories Inc. v. Lannett Holdings Inc.

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. June 28, 2018

    Fed. Circ. Backs AstraZeneca, Impax Win In Zomig Patent Suit

    The Federal Circuit on Thursday affirmed a Delaware federal court ruling that rejected arguments made by generic-drug maker Lannett Co. Inc. that two AstraZeneca AB nasal spray patents covering Impax's migraine drug Zomig are invalid, finding that it wasn't obvious to make the drug into a nasal spray.

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!